What drug interactions are known with Inrebic (fedratinib)?
“Inrebic interactions” usually refers to drug–drug interactions (and sometimes food/supplement interactions) that can change fedratinib levels or increase side effects. The most searched categories are:
- Strong CYP3A4 inhibitors and inducers (they can raise or lower fedratinib exposure).
- Drugs that also affect GI toxicity risk (since fedratinib can cause GI side effects).
- Agents that affect phosphate, since fedratinib can be associated with lab abnormalities including low phosphate.
- QT-prolonging or arrhythmia-risk medicines (patients often ask whether they can combine fedratinib with heart rhythm drugs).
If you tell me which medicines you’re taking (or the exact interaction you’re worried about), I can map it to the most relevant interaction type.
What happens if you combine Inrebic with a CYP3A4 inhibitor?
When fedratinib is combined with strong CYP3A4 inhibitors, fedratinib exposure can increase, which may raise the chance of adverse reactions. Typical clinical actions in such cases include closer monitoring and possible dose adjustment depending on the specific inhibitor and patient factors.
What happens if you combine Inrebic with a CYP3A4 inducer?
Strong CYP3A4 inducers can lower fedratinib exposure, which can reduce effectiveness. Clinicians typically avoid strong inducers when possible and switch to alternatives with less enzyme induction, or monitor response more closely.
Are there interactions with proton-pump inhibitors (PPIs) or acid reducers?
Patients frequently ask about acid-reducing therapy because it can change absorption for some oral cancer drugs. Whether a PPI changes fedratinib absorption depends on the drug’s formulation and label guidance for fedratinib. If you list the specific acid reducer (omeprazole, pantoprazole, famotidine, etc.), I can focus on that agent.
Does Inrebic interact with anticoagulants or antiplatelet drugs?
In myelofibrosis care, many patients also take anticoagulants or antiplatelet therapy. The key practical concern is whether fedratinib changes bleeding risk indirectly (for example through thrombocytopenia or drug-specific GI effects) or through metabolic interactions with specific anticoagulants. If you share the anticoagulant (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin), I can point to the main interaction questions clinicians check.
Any food or supplement interactions people should watch for?
Patients commonly ask about:
- Herbal supplements (especially those that affect CYP enzymes).
- High-dose vitamins/minerals (especially around phosphate if relevant).
- Grapefruit and other CYP-modulating foods.
If you share what you take (including supplements), I can flag the most likely interaction pathways.
Where do interaction details come from (label vs. clinical guidance)?
Interaction information for Inrebic is typically drawn from the prescribing information and drug-interaction studies, plus clinical guidance about dose adjustments when co-administering strong enzyme inhibitors/inducers.
If you paste your medication list, I’ll check the interaction pattern
To answer precisely, send:
1) Your Inrebic dose (e.g., 200 mg or other), and schedule
2) All prescription meds (including inhalers and heart meds)
3) OTC meds and supplements (especially herbs)
4) Any recent lab issues (phosphate, heart rhythm history)
Then I’ll summarize the likely interaction risks category-by-category (enzyme level changes, QT/arrhythmia concerns, bleeding/GI concerns, and lab monitoring).
Sources
I can’t provide interaction specifics yet because the necessary Inrebic interaction reference (prescribing information/table) wasn’t included in your message. If you want, paste the Inrebic interaction section/table from the label you’re using, and I’ll turn it into a clear interaction guide.